|
Age
|
60.2 ± 14.6, 62 (18–89)
|
58.9 ± 15.5, 62 (18–87)
|
61.1 ± 14, 62 (18, 89)
|
0.34
|
|
Gender (male)
|
59.3%
|
56.5%
|
61.1%
|
0.407
|
|
Type of malignancy
| | | |
0.609
|
|
Hematological
|
61.8%
|
58.9%
|
63.7%
|
0.385
|
|
Solid tumor
|
38.2%
|
41.1%
|
36.3%
| |
|
Metastatic disease
|
72.7%
|
92.7%
|
74.2%
|
0.035
|
|
Active disease (no remission)
|
86.8%
|
82.3%
|
89.6%
|
0.059
|
|
Stem cell transplant (yes)
|
31.6%
|
21.8%
|
18.1%
|
0.214
|
|
Co-morbidity index ≥ 5
|
68.5%
|
66.1%
|
69.9%
|
0.475
|
|
Chemotherapy within 10 days
|
24.3%
|
28.2%
|
21.8%
|
0.190
|
|
CNS malignancy involvement*
|
26.5%
|
33.9%
|
21.8%
|
0.017
|
|
Medical history of seizure disorder
|
10.4%
|
16.1%
|
10.9%
|
0.008
|
|
Medical service
|
89.3%
|
83.0%
|
94.8%
|
0.006
|
|
Variables during ICU stay
| | | | |
|
SOFA on admission**
|
8.5 ± 3.7, 8 (0–19)
|
7.2 ± 3.3, 7 (0–16)
|
9.3 ± 3.8, 9 (2–19)
|
< 0.0001
|
|
SOFA at time of EEG #
|
9.9 ± 4.0, 10 (3–22)
|
8.2 ± 3.7, 7 (3–21)
|
11.1 ± 3.7, 11 (3–22)
|
< 0.0001
|
|
GCS at time of EEG## (median)
|
7 (3–12)
|
8 (3–12)
|
7 (3–12)
|
0.001
|
|
Vasopressors (yes)
|
56.5%
|
35.5%
|
69.9%
|
< 0.0001
|
|
Acute renal failure (yes)
|
52.4%
|
31.5%
|
65.8%
|
< 0.0001
|
|
Mechanical Ventilation (yes)
|
79.5%
|
66.9%
|
87.6%
|
< 0.0001
|
|
Use of sedatives (yes)
|
49.8%
|
44.4%
|
53.4%
|
0.117
|
|
Cardiac arrest during ICU stay
|
13.3%
|
3.2%
|
19.7%
|
< 0.0001
|
